PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24395436-5	2014	However, in event pattern analyses considering only the patients with TPMT(LA) who experienced relapse or SMN, the risk of SMN versus leukemia relapse was significantly lower in the ALL2000 cohort for patients with a 6MP starting dose <75 mg/m(2)/day when compared to the patients in ALL92 (relapse (n = 11) and SMN (n = 0) in ALL2000 versus relapse (n = 5) and SMN (n = 4) in ALL92, P = 0.03).	(S)-(+)-Mandelic acid	106-109	thiopurine S-methyltransferase	Homo sapiens	70-74	
24395436-7	2014	CONCLUSION: This study indicates that reducing 6MP starting dose for patients with TPMT(LA) may reduce SMN risk but lead to a relapse risk similar to that of patients with TPMT(WT).	(S)-(+)-Mandelic acid	103-106	thiopurine S-methyltransferase	Homo sapiens	83-87	
19224761-5	2009	Of 524 patients who had erythrocyte TPMT activity measured, the median TPMT activity in 9 patients developing an SMN was significantly lower than in the 515 that did not develop an SMN (median, 12.1 vs 18.1 IU/mL; P = .02).	(S)-(+)-Mandelic acid	113-116	thiopurine S-methyltransferase	Homo sapiens	36-40	
19224761-5	2009	Of 524 patients who had erythrocyte TPMT activity measured, the median TPMT activity in 9 patients developing an SMN was significantly lower than in the 515 that did not develop an SMN (median, 12.1 vs 18.1 IU/mL; P = .02).	(S)-(+)-Mandelic acid	113-116	thiopurine S-methyltransferase	Homo sapiens	71-75	
19224761-6	2009	Among 427 TPMT wild-type patients for whom the 6MP dose was registered, those who developed SMN received higher average 6MP doses than the remaining patients (69.7 vs 60.4 mg/m2; P = .03).	(S)-(+)-Mandelic acid	92-95	thiopurine S-methyltransferase	Homo sapiens	10-14